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The recent development and spread of extensively drug-resistant and totally drug-resistant resistant (TDR) strains ofMycobacte-
rium tuberculosis highlight the need for new antitubercular drugs. Protein synthesis inhibitors have played an important role in
the treatment of tuberculosis (TB) starting with the inclusion of streptomycin in the first combination therapies. Although par-
enteral aminoglycosides are a key component of therapy for multidrug-resistant TB, the oxazolidinone linezolid is the only
orally available protein synthesis inhibitor that is effective against TB. Here, we show that small-molecule inhibitors of amino-
acyl-tRNA synthetases (AARSs), which are known to be excellent antibacterial protein synthesis targets, are orally bioavailable
and effective againstM. tuberculosis in TBmouse infection models. We applied the oxaborole tRNA-trapping (OBORT) mecha-
nism, which was first developed to target fungal cytoplasmic leucyl-tRNA synthetase (LeuRS), toM. tuberculosis LeuRS. X-ray
crystallography was used to guide the design of LeuRS inhibitors that have good biochemical potency and excellent whole-cell
activity againstM. tuberculosis. Importantly, their good oral bioavailability translates into in vivo efficacy in both the acute and
chronic mouse models of TB with potency comparable to that of the frontline drug isoniazid.
The aminoacyl-tRNA synthetases (AARSs) are a family of es-sential enzymes that are required for protein synthesis in all
cells (1). Although various family members have been targeted
for the design of novel antibacterials (2), only the isoleucyl-
tRNA synthetase inhibitor mupirocin is an FDA-approved an-
tibiotic (3). However, mupirocin is approved only for the top-
ical treatment of staphylococcal and streptococcal skin
infections (3), and Mycobacterium tuberculosis is naturally resis-
tant to this agent (4). Leucyl-tRNA synthetase (LeuRS) is a class
I AARS that has two active sites separated by a distance of 30 Å,
a synthetic site that aminoacylates tRNALeu, and an editing site
that ensures the fidelity of translation by a proofreading mech-
anism (5–8). Recently, boron-containing compounds known
as oxaboroles have been shown to inhibit LeuRS by the oxa-
borole tRNA-trapping (OBORT) mechanism (9), which ex-
ploits the ability of the boron atom to bond to the cis-diols of
the 3=-terminal adenosine nucleotide Ade76 of tRNALeu. The
resulting covalent adduct traps the 3= end of tRNALeu in the
editing site in a nonproductive complex, inhibiting leucylation
and thereby protein synthesis (9). Here, we report the discov-
ery of novel 3-aminomethyl derivatives that have potent anti-
tubercular activity.
MATERIALS AND METHODS
Chemical synthesis. The syntheses of the compounds are described in
detail in the supplemental material.
Expression, purification, and crystallization of the M. tuberculosis
LeuRS editing domain. A DNA fragment coding for the region spanning
G309 to I513 of M. tuberculosis LeuRS (UniProt accession number
P67510) was cloned into pETM-11 by using the NcoI and XdeI restriction
sites (EMBL). The protein containing an N-terminal six-histidine tag was
prepared and purified according to a protocol similar to the one described
previously for Escherichia coli LeuRS (8), except that nickel affinity chro-
matography was conducted at pH 8.0. Protein was stored in buffer com-
prising 20 mM Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM MgCl2, and 5
mM 2-mercaptoethanol. Crystallization was performed at 20°C by the
hanging-drop vapor diffusion method. The solutions for the ternary com-
plexes were prepared with 10 mg/ml LeuRS, 5 mM AMP, and 1 mM the
corresponding benzoxaborole compound (provided by Anacor Pharma-
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ceuticals, Palo Alto, CA). Initial crystals were obtained at 15 mg/ml LeuRS,
5 mM AMP, and 1 mM the corresponding benzoxaborole compound
(provided by Anacor Pharmaceuticals, Palo Alto, CA). Crystals were ob-
tained by mixing 2 l of this solution with 2 l of a reservoir solution
containing 0.1 M Bis-Tris (pH 5.5), 22% (wt/vol) polyethylene glycol
10000 (PEG 10000), and 0.2 M ammonium acetate. The quality and size of
the final diffracting crystal were improved by decreasing the LeuRS con-
centration to 10 mg/ml and decreasing the PEG 10000 concentration to
17% (wt/vol). The crystals were frozen directly in liquid nitrogen in
mother liquor containing 15% (vol/vol) ethylene glycol as a cryopro-
tectant.
Structure determination and refinement. All diffraction data sets
were collected at the European Synchrotron Radiation Facility (ESRF,
Grenoble, France). Data were integrated and scaled with the XDS suite
(10). Further data analysis was performed with the CCP4 suite (11). The
structure of the LeuRS:AMP-compound 6 complex was initially solved by
molecular replacement with PHASER (12), using the E. coli LeuRS editing
domain structure (13) (PDB accession number 2AJG) as a model. The
model was improved by automatic building using ARP-wARP (14), and
manual adjustments were made with COOT (15). The structures of the
complexes with compounds 14 and 16 were solved by using the editing
domain ofM. tuberculosis LeuRS (described above) as a model. All models
were refined by using REFMAC5 with anisotropic B-factors. Structure
quality was analyzed with MOLPROBITY (16) (http://molprobity
.biochem.duke.edu/) and showed all residues in allowed regions (with
95.1 to 98.0% of residues in favored regions) for the different models.
Figures were drawn with PYMOL (http://www.pymol.org/).
Aminoacylation assay. N-terminal six-histidine-tagged LeuRS from
M. tuberculosis H37Rv, which was codon optimized for E. coli (GenScript,
Piscataway, NJ, USA), was overexpressed and purified according to the
manufacturer’s instructions (Novagen, Madison, WI, USA), using an E.
coli BL21(DE3) T7 RNA polymerase overexpression strain. Experiments
were performed in 96-well microtiter plates, using 80-l reaction mix-
tures containing 50 mM HEPES-KOH (pH 8.0), 30 mM MgCl2, 30 mM
KCl, 13 M L-[14C]leucine (306 mCi/mmol; Perkin-Elmer), 15 M total
E. coli tRNA (Roche, Switzerland), 0.02% (wt/vol) bovine serum albumin
(BSA), 1 mM dithiothreitol (DTT), 0.2 pM LeuRS, and 4 mM ATP at
30°C. Reactions were started by the addition of 4 mM ATP to the mix-
tures. After 7 min, reactions were quenched, and tRNA was precipitated by
the addition of 50 l of 10% (wt/vol) trichloroacetic acid (TCA) and trans-
ferred to 96-well nitrocellulose membrane filter plates (Multiscreen HTS,
catalog number MSHAN4B50; Millipore). Each well was then washed three
times with 100l of 5% TCA. Filter plates were then dried under a heat lamp,
and the precipitated L-[14C]leucine tRNALeu was quantified by liquid scintil-
lation counting using a Wallac MicroBeta Trilux model 1450 liquid scintilla-
tion counter (PerkinElmer, Waltham, MA, USA).
IC50 determination. To determine the inhibitor concentration that
reduces enzyme activity by 50% (IC50), increasing concentrations of com-
pound inhibitors that covered the IC50 were incubated with LeuRS en-
zyme, tRNA, and L-leucine for 20 min. Reactions were initiated by the
addition of 4 mM ATP to the mixtures. Reactions were stopped after 7
min, and the enzyme was then precipitated and quantified to determine
radioactivity. IC50 values were determined by using a 4-parameter logistic
nonlinear regression model (GraphPad Software Inc., La Jolla, CA, USA).
Isothermal titration calorimetry experiments. Isothermal titration
calorimetry (ITC) experiments were performed at 25°C by using an
ITC200 system (MicroCal; GE Healthcare). The editing domain protein
was dialyzed for 12 h against titration buffer (50 mM HEPES-KOH, 30
mM KCl, and 30 mM MgCl2 [pH 8.0]) at 4°C. Protein solutions at 50M
plus AMP at 10 mM in the calorimetric cell were titrated with the appro-
priate compound dissolved in dialysis buffer. Compound solutions at 1 to
5 mM plus AMP at 10 mM were incubated at 37°C during 1 h before
titrations. The heat evolved after each ligand injection was obtained from
the integral of the calorimetric signal. The resulting binding isotherms
were analyzed by nonlinear least-squares fitting of the experimental data
to a single-site model. Analysis of the data was performed by using Micro-
Cal Origin software (OriginLab version 7). Experiments were performed
at least twice. The variability in the binding experiments was estimated to
be 5% for binding enthalpy and 10% for both the binding affinity and the
number of sites.
Determination of MIC values for M. tuberculosis. MIC values were
determined mainly by using resazurin (alamarBlue) as an indicator for
cell growth (17), with additional determinations being performed as de-
scribed previously by Ollinger et al. (18).
Selection of Mycobacterium smegmatis ATCC 700084 single-step
mutants.Mutants resistant to compound 1 were isolated on Middlebrook
7H10 medium plus 10% (vol/vol) oleic albumin dextrose catalase
(OADC) supplement (Becton Dickinson) containing compound 1 at 4
MIC. Resistance was confirmed by measuring the mutant MIC values
essentially as described previously by Collins and Franzblau (17).
Selection ofM. tuberculosis single-stepmutants.M. tuberculosismu-
tants resistant to compounds 1 and 13 were isolated as described previ-
ously by Ioerger et al. (19). Mutants were isolated on Middlebrook 7H10
medium plus 10% (vol/vol) OADC (Becton Dickinson) containing com-
pounds 1 and 13 at 5 or 10 MIC99. Resistance was confirmed by
measuring the MIC99 (20). Genome sequencing and identification of
polymorphisms were carried out essentially as described previously by
Ioerger et al. (19). In order to determine the rate of spontaneously resis-
tant mutants, M. tuberculosis H37Rv bacteria were grown at 37°C in fresh
Middlebrook 7H9 medium-ADC-Tween 80 to mid-exponential phase
and then diluted in fresh Middlebrook 7H9 medium-ADC-Tween 80 to
5  108 CFU/ml. Middlebrook 7H10-OADC agar plates with 4- and 10-
fold MIC values of each compound were inoculated with 108, 107, 106, and
105 CFU/plate, and the plates were incubated at 37°C for 3 to 4 weeks. The
frequency of the appearance of resistant mutants was calculated, and iso-
lated colonies were restreaked onto Middlebrook 7H10-OADC agar con-
taining the drugs and onto plates without the drug.
Time-kill assay. Compounds were added at 20 MIC to a 10-ml
exponential-phase culture of M. tuberculosis H37Rv (5 105 CFU/ml)
in Middlebrook 7H9 medium with 10% (vol/vol) OADC and 0.05% (vol/
vol) Tween 80. At the specified time points, aliquots of cultures were
withdrawn, serially diluted, and plated onto solid culture medium. Plates
were then incubated at 37°C, and CFU were counted after 3 to 4 weeks.
In vitro cytotoxicity assay. Vero epithelial cells (from African green
monkey; ATCC CCL-81) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and
maintained in a humidified incubator (37°C in 5% CO2). Cells were dis-
lodged with a cell scraper, collected by centrifugation, resuspended in
fresh medium at 106 cells/ml, dispensed into 96-well microtiter plates
(100 ml/well), and incubated for 18 h at 37°C. Twofold serial dilutions of
test compounds in DMEM with FBS were subsequently added, and cells
were incubated for another 72 h. In triplicate studies, the cytopathic ef-
fects of compounds were evaluated colorimetrically by using the 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) cell
proliferation assay (ATCC). IC50 data were obtained from dose-response
curves plotted by using GraphPad Prism 5.
Mitochondrial protein synthesis assay. The human liver carcinoma-
derived HepG2 cell line was obtained from the ATCC (ATCC HB-8065).
HepG2 cells were grown in Dulbecco’s modified Eagle’s medium contain-
ing 10% fetal calf serum, 1 mM sodium pyruvate, 0.1 mM essential amino
acids, and 50 U/ml penicillin-streptomycin at 37°C with 5% CO2. HepG2
cells were seeded into 96-well plates at 3,000 cells/200 l/well in cell cul-
ture medium. Cells were then grown in the presence of the compounds at
37°C in 10% CO2 for 7 days in at least duplicate concentrations, with the
medium and compounds being replaced on the fourth day. After 7 days,
the levels of SDHA (subunit A of the succinate dehydrogenase complex)
and COX1 (cytochrome c oxidase) were determined by using the Mito-
Sciences In-Cell enzyme-linked immunosorbent assay (ELISA) kit. Janus
green staining was used to determined cell viability after 7 days (In-Cell
ELISA kit, catalog number MS643).
Palencia et al.
6272 aac.asm.org October 2016 Volume 60 Number 10Antimicrobial Agents and Chemotherapy
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
Mouse pharmacokinetic analysis. Mouse pharmacokinetic studies
were conducted by using female CD-1 mice for compounds 1, 11, and 12,
while BALB/c mice were used for compound 13. Mouse body weights
were 19 to 28 g, and on the morning of dosing, mice were split randomly
into 3 dosing groups to receive the test article by either intravenous (i.v.)
tail vein injection or oral (p.o.) gavage. After dosing, blood samples were
collected via cardiac puncture at specific time points (n  3 mice/time
point) through 24 h (K2EDTA as an anticoagulant) and processed for
plasma. Antibiotic concentrations in the plasma samples were analyzed by
liquid chromatography-tandem mass spectrometry (LC-MS/MS). The
LC-MS/MS analysis was conducted by using analyte/internal standard
peak area methods. The internal standard was AN3365 (21), and the in-
strument used was an API4000 QTRAP instrument (AB Sciex). The limit
of quantitation (LOQ) was 1 or 2 ng/ml. Pharmacokinetic analyses of the
mean plasma concentration-time profiles were performed by using Win-
Nonlin Pro version 5.2. A compartmental model was used for the data for
i.v. dosing, and a noncompartmental model was used for the data for p.o.
dosing. The concentration-time curve after an i.v. dose showed a biexpo-
nential decline with first-order elimination. Compounds 1 and 13 were
formulated in saline (0.9% [wt/vol] NaCl) at 7.5 mg/ml, and the pH was
adjusted to5 by the addition of NaOH. Compound 11 was formulated
to 6.5 mg/ml in water-dimethylacetamide-ethanol (EtOH) (76:19:5), and
the pH was adjusted to5 by the addition of NaOH. Compound 12 was
formulated to 7.5 mg/ml in PEG 300-propylene glycol (PG)-water (55:25:
20), and the pH was adjusted to5 by the addition of NaOH.
Mouse plasma protein binding determination. Compounds were
added to 1.5-ml aliquots of mouse plasma at concentrations of 1 and 10
g/ml and then incubated in a shaking water bath at 37°C for 15 min. Both
samples were treated similarly, and a 0.5-ml aliquot was removed from
each tube and added to the filter reservoir of Microcon centrifugal filter
devices (Ultracel YM-30 with a molecular mass cutoff of 30 kDa). The
devices were centrifuged at 1,000 g for 10 min, and 100l of the filtrate
was transferred to a 96-well plate and diluted 5-fold. Ten-microliter vol-
umes of the samples were injected and analyzed with the LC-MS/MS
system. All samples were analyzed in duplicate. Quantitation was based on
the peak area ratio of the analyte over the internal standard, and all inte-
grations were performed with peak areas by using Analyst version 1.4.1
(Applied Biosystems, Foster City, CA, USA). Plasma protein binding was
calculated based on the following equation:
Plasma Protein Binding ( % )

PeakAreaPlasma UltrafilrateSpiked  PeakAreaPlasmaFiltrate
PeakAreaPlasma Ultrafiltrate
Spiked  100
Murine model of acute tuberculosis (TB) infection using C57BL/6
GKO IFN- mice. Eight- to 10-week-old female specific-pathogen-free
C57BL/6-Ifngtm1ts mice (gamma interferon [IFN-] gene-disrupted
[gene knockout {GKO}] mice) were purchased from Jackson Laboratories
(Bar Harbor, ME). The mice were infected with M. tuberculosis Erdman
via a low-dose aerosol exposure in a Middlebrook aerosol generation de-
vice (Glas-Col Inc., Terre Haute, IN) as described previously (22). At 1 day
postaerosol, three mice were sacrificed to verify the uptake of 50 to 100
CFU of bacteria per mouse. Each treatment group consisted of five mice,
and treatment was started at 10 to 13 days postinfection and continued for
9 or 14 consecutive days. Five infected mice were sacrificed at the start of
treatment as pretreatment controls. Drugs were administered daily by oral
gavage. Lungs were harvested 24 h after the last administration, and all
lung lobes were aseptically removed, homogenized, and frozen. Homog-
enates were plated onto 10% OADC–Middlebrook 7H11 medium for 21
days at 37°C. All animal studies strictly adhered to the protocols and
regulations approved by the respective Animal Care and Use Committees
of the University of Illinois at Chicago and Colorado State University.
Murine model of acute and chronic TB infections using C57BL/6J
mice. Specific-pathogen-free 8- to 10-week-old female C57BL/6 mice
were purchased from Harlan Laboratories and were allowed to acclimate
for 1 week. The experimental design for the acute-infection assay was
previously described (23). In brief, for the acute-infection assay, mice
were intratracheally infected with 100,000 CFU/mouse (M. tuberculosis
H37Rv strain). Products were administered for 8 consecutive days starting
1 day after infection. For the chronic-infection assay, mice were intratra-
cheally infected with 100 CFU/mouse, and the products were adminis-
tered daily (7 days a week) for 8 consecutive weeks starting 6 weeks after
infection. Lungs were harvested 24 h after the last administration. All lung
lobes were aseptically removed, homogenized, and frozen. Homogenates
were plated onto 10% OADC–Middlebrook 7H11 medium and incubated
for 21 days at 37°C. The viable CFU were converted to logarithms, which
were then evaluated by one-way analysis of variance, followed by multi-
ple-comparison analysis of variance by a one-way Tukey test (SigmaStat
software program). Differences were considered significant at the 95%
level of confidence. All animal studies were ethically reviewed and carried
out in accordance with European Directive 2010/63/EU and GlaxoSmith-
Kline (GSK) policy on the care, welfare, and treatment of animals.
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FIG 1 In vitro structure-activity relationships. M.tb, M. tuberculosis; NT, not
tested.
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Murine model of chronic TB infection using BALB/c mice. Six- to
8-week-old female specific-pathogen-free immunocompetent BALB/c
mice (Charles River, Wilmington, MA) were infected with M. tuberculosis
Erdman via low-dose aerosol exposure as described previously (22). At 1
day postaerosol, three mice from each run were sacrificed to verify the
uptake of 50 to 100 CFU of bacteria per mouse. Each group consisted of
five to six mice at each time point. Treatment was started at 3 weeks
postinfection and continued for 12 weeks. Five infected mice were sacri-
ficed at the start of treatment as pretreatment controls. Drugs were ad-
ministered 5 days per week by oral gavage for 4 weeks. Lungs were har-
vested 72 h after the last administration. All lung lobes were aseptically
removed, homogenized, and frozen. Homogenates were plated onto
10% OADC–Middlebrook 7H11 medium and incubated for 21 days at
37°C. All animal studies strictly adhered to the protocols and regula-
tions approved by the Colorado State University Animal Care and Use
Committee.
Accession numbers. Atomic coordinates and structure factors for
compounds 2, 11, and 13 have been deposited with the Protein Data Bank
(PDB) under accession numbers 5AGR, 5AGS, and 5AGT, respectively.
RESULTS AND DISCUSSION
Discovery of antitubercular LeuRS inhibitors. A focus library of
20 benzoxaboroles was initially screened against M. tuberculosis
H37Rv, which yielded AN3016 and AN3017, with MIC values of 1
g/ml and 1.8g/ml and LeuRS half-maximal inhibitory concen-
trations (IC50) of 3.5M and 0.64M, respectively (Fig. 1). When
we incorporated both the 3-aminomethyl and the 7-ethoxy sub-
stitutions into one moiety, compound 1, it gave significantly bet-
ter activity, with a LeuRS IC50 of 0.28 M and an MIC of 0.26
g/ml (Fig. 1). To confirm that compound 1 was targeting LeuRS
in the cell, we obtained resistant mutants ofM. tuberculosisH37Rv
and Mycobacterium smegmatis ATCC 700084. The leuS gene,
which codes for LeuRS, was sequenced from the selected resistant
mutants, and mutations were found in both organisms, which was
consistent with an OBORT LeuRS inhibitor (Fig. 2 and Table 1).
Therefore, we progressed compound 1 into an in vivo mouse
pharmacokinetic study to determine suitability for testing in a
mouse model of acute TB infection. Compound 1 was dosed by
oral administration (p.o.) at 30 mg/kg of body weight, which
yielded an area under the concentration-time curve from 0 to
24 h (AUC0 –24) of 15 h ·g/ml, with a maximum concentration in
plasma (Cmax) of 4.33g/ml and oral bioavailability of 55% (data
not shown). Since the existing in vivo efficacy mouse model used
M. tuberculosis Erdman and not M. tuberculosis H37Rv, the MIC
of compound 1 was confirmed against the Erdman strain as well as
some drug-resistant isolates (Table 2). The M. tuberculosis Erd-
man MIC value was 0.127g/ml, which was not affected by mech-
anisms of resistance to rifampin, isoniazid (INH), or streptomy-
cin. Compound 1 was then tested in a BALB/c mouse model of
acute TB infection at a dose of 100 mg/kg twice a day (BID) for 3
weeks with weekend drug holidays. The control drug PA-824
(pretomanid) (24) was dosed at 100 mg/kg once a day (QD),
which gave a 1.9-log10 reduction in CFU from mouse lungs, com-
pared to only a 0.4-log10 reduction in CFU for compound 1 (data
not shown). Therefore, we separated the two enantiomers in com-
pound 1 by chiral high-performance liquid chromatography
(HPLC) and determined their activities (Fig. 1). The active enan-
tiomer was the (S)-isomer, compound 2, which had a LeuRS IC50
of 0.13 M and an MIC of 0.13 g/ml, while the (R)-isomer was
FIG 2 Compound 1-resistant mutants bear mutations in the editing domain of LeuRS. (A) Domain map of M. tuberculosis LeuRS. (B) Amino acid alignment of
part of the editing domain of LeuRS fromM. tuberculosis andM. smegmatis. Identical residues are shown in blue, and nonidentical residues are shown in red, with
arrows indicating where the mutations were found.
TABLE 1 MIC values for compound 1-resistant mutantsa
Organism MIC (g/ml)b
M. tuberculosis
H37Rv 0.6–1.3
RM1leuS Y435C 21
RM2leuS S311L 21
RM3leuS D450Y 21
RM4leuS S311L 21
M. smegmatis
ATCC 700084 1
RM1leuS 421–462 256
RM2leuS A428T 64
RM3leuS R435C 8
RM4leuS A428T 64
a Residues Y435 and D450 stabilize the adduct formed by compound 1 with AMP in the
editing site of M. tuberculosis LeuRS (Fig. 4B). Residue S311, like the equivalent E. coli
LeuRS residue (13), interacts with the phosphate of Ade76, thus stabilizing the adduct
in the editing site. However, S311 is located at the flexible N-terminal part of our
editing domain construct of M. tuberculosis LeuRS and thus is not visible in the crystal
structure (Fig. 4B). RM, resistant mutant.
b MIC values for M. tuberculosis were determined on agar, and those for M. smegmatis
were determined in liquid cultures.
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barely active, with an IC50 of 21 M. The active enantiomer com-
pound 2 was then tested at 200 mg/kg BID for 9 days in the model
of acute TB infection by using an IFN- gene knockout (GKO)
mouse (25), which showed a 2-log10 reduction in lung CFU and a
1.5-log10 reduction in spleen CFU compared to control mice (Fig.
3). However, this was not as good as the frontline drug INH, which
gave 2.8- and 3.4-log10 reductions in CFU from lungs and spleen,
respectively, when dosed at 25 mg/kg.
M. tuberculosis LeuRS inhibitor cocrystallization. In order to
improve potency, we performed structural and biophysical stud-
ies to understand the mode of binding of these novel 3-amino-
methyl benzoxaboroles to M. tuberculosis LeuRS. Crystallization
trials with different editing domain constructs of M. tuberculosis
LeuRS were attempted in the presence of compound 2 with either
AMP or longer nucleotides such as CytAde or CytCytAde, which
might act as surrogates for the 3= end of the tRNA acceptor stem
(26). An editing domain construct encompassing residues G309
to I513 gave cocrystals with compound 2 and AMP that diffracted
to a 1.3-Å resolution, which permitted structure determination
(Fig. 4A and B; see also Table S1 in the supplemental material).
Compound 2 forms a bidentate covalent adduct with AMP (Fig.
4B), which mimics Ade76 of the tRNA acceptor end (7, 8, 21).
Amino acid residues T336 to T337 of the threonine-rich region
provide multiple H-bonding interactions to the covalent adduct,
and L432 and Y435 of the AMP binding loop have extensive H-
bonding and hydrophobic contacts with AMP (Fig. 4B). In addi-
tion, the amino group of compound 2 makes three key interac-
tions with the carboxylic acid side chains of D447 and D450 and
the carbonyl group of M441. The 7-ethoxy substitution not only
enables a new interaction with R449 but also packs with the Ade76
ribose, thus further stabilizing the boron-tRNA adduct (Fig. 4B).
Superposition of the compound 2 adduct-bound structure with
that of the E. coli LeuRS editing domain with methionine bound
(13) shows that the 3-aminomethyl benzoxaborole moiety occu-
pies the same position as the noncognate amino acid (Fig. 4C).
Although this moiety mimics the interactions established by the
amino and the oxygen carbonyl groups of methionine, it lacks
atoms at the positions of the S	-Cε atoms of methionine (Fig. 4C),
which suggests that there is additional space to make further in-
teractions.
Structure-activity relationship of potent antitubercular
agents. Several derivatives were synthesized with different substi-
tutions at position 4 as well as at positions 5 and 6 to explore this
hypothesis (Fig. 1). The halogen substitutions 5-Cl (compound 5)
and 6-F (compound 7) were not well tolerated, with LeuRS activ-
ity being worse than the original compound 1 and MIC values of
1.1 g/ml or greater. The most potent analogs were compounds
with halogen substitutions at position 4, bromo (compound 11),
chloro (compound 4), and fluoro (compound 6) substitutions,
which improved MIC values more than 5-fold over those com-
pound 1 (Fig. 1). The phenyl (compound 10) substitution was not
tolerated, with a LeuRS IC50 of 28 M (Fig. 1). However, it must
be noted that the significant improvements in MIC values for
compounds 4, 6, and 11 were not fully reflected in their IC50 values
as determined by using an aminoacylation assay with M. tubercu-
losis LeuRS, which could be due to the way in which OBORT
inhibitors indirectly inhibit aminoacylation by preventing bind-
ing of Ade76 to the aminoacylation active site (9). We therefore
decided to measure the direct binding of the compounds to the
editing domain using isothermal titration calorimetry (ITC) and
found that the 4-Cl and 4-Br substitutions significantly enhanced
the affinity of the compounds for the M. tuberculosis LeuRS edit-
ing domain (Table 3). This increased affinity is due to a significant
gain in the enthalpic contribution (3.1 to 4.4 kcal mol
1), which is
consistent with additional favorable interactions being established
by the halogen atoms in the editing site. To confirm that whole-
cell activity was derived from the inhibition of LeuRS, we selected
6 M. tuberculosis mutants resistant to compound 13 and se-
quenced their leuS genes, while two additional mutants were se-
lected for whole-genome sequencing. All 8 resistant mutants had a
single nucleotide polymorphism (SNP) in their leuS genes, and the
mutations were located in the editing domain, as expected for
OBORT LeuRS inhibitors (9, 21, 27) (see Table S2 in the supple-
mental material). To further explore interactions at the 4-posi-
tion, we cocrystallized compounds with 4-Cl and 4-Br substitu-
tions in the presence of AMP and solved the structures of the
ternary complexes at 1.45- and 1.47-Å resolutions, respectively
(see Table S1 and Fig. S1 in the supplemental material). The struc-
tures showed that the halogenated compounds bind to the editing
site without major structural changes, and as predicted, the
4-Cl/Br atoms now occupied the position of the sulfur in bound
TABLE 2 Compound 1 MIC values against M. tuberculosis Erdman and
monoresistant isolates compared with known standardsa
Strain
MIC (g/ml)
Compound 1 PA-824 RIF INH STR
M. tuberculosis Erdman 0.127 0.116 0.018 0.244 0.369
RIFr 0.120 0.128 4 0.383 0.216
INHr 0.059 0.063 0.037 8 0.202
STRr 0.113 0.189 0.082 0.344 16
a RIF, rifampin; INH, isoniazid; STR, streptomycin; RIFr, strain with resistance to
rifampin.
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FIG 3 In vivo efficacy of compound 2 (Cmp 2) in a murine GKO (C57BL/6-
Ifngtm1ts) model of acute TB. Oral treatment was started 15 days (start) after
infection with a low-dose aerosol ofM. tuberculosis Erdman lux and continued
for 9 consecutive daily treatments until day 23, when mice were euthanized on
day 24 (end). CFU in lungs and spleens were determined, and means from five
mice for drug-treated groups and from 6 mice per group for the untreated
controls are shown. *, P 0.001 by pairwise multiple-comparison procedures
(Tukey test) compared to controls.
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methionine (see Fig. S2A in the supplemental material), allowing
van der Waals interactions with the neighboring protein atoms
(see Fig. S2B in the supplemental material). These results con-
firmed the importance of the size and nature of the substitution at
position 4 and agreed well with the in vitro activities and thermo-
dynamic analyses (see Fig. S2C in the supplemental material).
We selected the three most potent compounds, compounds 11,
12, and 13, for in vivo murine pharmacokinetic analysis, and we
dosed mice both i.v. and p.o. All three compounds showed im-
provements in plasma exposure as measured by AUC after oral
administration over compound 2 (Table 4). Therefore, we tested
them in a GKO mouse model of acute TB, which showed that all
three compounds were very efficacious, with racemate compound
11 having efficacy similar to that of isoniazid (Fig. 5A and B). In a
BALB/c mouse model of chronic TB infection, all compounds
showed good efficacy (Fig. 5C), with compound 14, the (S)-iso-
mer of compound 11, being the most potent. In addition, we
observed that compounds 13 and 14 did not show any cross-resis-
tance against multidrug-resistant isolates (see Table S3 in the sup-
plemental material).
Inhibition of mitochondrial protein synthesis. Although
protein synthesis inhibitors are validated TB drugs, they are asso-
ciated with some safety concerns, for example, myelosuppression
and neuropathy observed with linezolid (28) and deafness in-
duced by aminoglycosides (29). The similarity between the bacte-
rial and mitochondrial protein synthesis machineries (30) and
their subsequent inhibition of mitochondrial protein synthesis is
thought to drive these toxicities. Therefore, we tested the ability of
compound 14 and some close analogs to inhibit mitochondrial
FIG 4 X-ray cocrystal structure of LeuRS with compound 2. (A) Crystal structure of the M. tuberculosis LeuRS editing domain in complex with compound 2
(carbon atoms are shown in green)-AMP (carbon atoms are shown in magenta). Color coding is the same throughout all figures, with blue for nitrogen, red for
oxygen, pink for boron, orange for phosphorus, and yellow for sulfur. (B) Zoomed view into the editing site of M. tuberculosis LeuRS showing the compound
2-AMP adduct and the key residues establishing important hydrogen bonds (red dashed lines), with only the H bond from the 3-aminomethyl to M441 being
omitted for clarity. (C) Overlay of the LeuRS editing domain ofM. tuberculosis andE. coli in complex with methionine (in yellow) (PDB accession number 2AJH).
The 3-aminomethyl group of compound 2 mimics the amino group of methionine, including the interaction with the bacterium-specific residue D447.
TABLE 3 Thermodynamic analysis of interactions between M.
tuberculosis LeuRS and benzoxaborole compoundsa
Compound
Kd
(M)
Gap
(kcal mol
1)
Hap
(kcal mol
1)

TSap
(kcal mol
1)
No. of
sites
2 3.7 
7.4 
1.1 
6.3 1.05
13 0.075 
9.7 
4.2 
5.5 1.19
11 0.040 
10.0 
5.5 
4.6 1.02
a The errors in the thermodynamic binding parameters are5% for the apparent
binding enthalpy and 10% for the apparent binding constant and the number of sites.
Kd, dissociation constant; G, change in Gibb’s free energy; H, change in enthalpy;
S, change in entropy. Values are the averages of data from at least 2 independent
experiments.
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protein synthesis in the human liver carcinoma cell line HepG2
(Table 5). The ribosomal protein synthesis inhibitors linezolid,
chloramphenicol, and doxycycline inhibited the synthesis of the
mitochondrially derived COX1 protein with 50% effective con-
centrations (EC50) of between 23 and 31M, while erythromycin
and compounds 12, 13, and 14 had EC50 of 150 M. Although
this could be due to poor mitochondrial penetration, it is interest-
ing to note that human mitochondrial LeuRS is known to be ed-
iting defective, as it lacks key conserved amino acid residues in the
AMP binding loop and amine binding pocket (31).
TABLE 4 Murine pharmacokinetic parameters
Parametera
Value for compound:
2 11 12 13 14
i.v.b
Dose (mg/kg) 30 15 30 30 30
Cmax (g/ml) at 5 min 8.9 18.0 13.7 13.6 17.1
CL (ml/h/kg) 2,180 328 1,119 582 687
Vss (ml/kg) 2,116 968 3,805 3,142 3,221
MRT (h) 2.1 3.0 3.4 5.4 4.7
AUC0– (h · g/ml) 13.8 45.8 26.8 51.6 43.7
-t1/2 (h) (% AUC) 0.06 (5) 0.09 (2) 0.11 (7) 0.10 (2) 0.05 (5)
-t1/2 (h) (% AUC) 1.5 (95) 2.08 (98) 2.53 (93) 3.83 (98) 3.40 (95)
p.o.c
Dose (mg/kg) 30 30 30 30 30
Cmax (g/ml) 3.4 7.2 5.0 6.4 6.3
Tmax (h) 0.50 1.00 1.00 0.25 0.50
AUC0–24 (h · g/ml) 13.2 35.9 23.8 47.5 57.6
Terminal t1/2 (h) 1.8 2.7 2.7 3.1 3.6
Bioavailability (%) 96 39 89 92 100
Mouse PPB (%) 6 50 16 23
a CL, clearance; Vss, volume of distribution at steady state; MRT, mean residence time;
t1/2, half-life; Tmax, time to maximum concentration of drug in serum. PPB, plasma
protein binding.
b WinNonlin two-compartment analysis with iterative weighting.
c WinNonlin noncompartmental analysis with uniform weighting.
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FIG 5 In vivo efficacy of compounds 11, 12, 13, and 14 in models of acute and chronic of TB infections. (A) In vivo efficacy in a murine GKO (C57BL/6-
Ifngtm1ts) model of acute TB. Compounds were dosed orally daily for 14 days after 10 days of infection (start) with a low-dose aerosol ofM. tuberculosis Erdman.
Mean lung CFU were determined from five mice at the end. (B) In vivo efficacy in a murine GKO (C57BL/6-Ifngtm1ts) model of acute TB. Oral treatment was
started 13 days after infection (start) with a low-dose aerosol of M. tuberculosis Erdman lux and continued for 9 consecutive daily treatments until day 21, when
mice were sacrificed on day 22 (end). Mean lung CFU were determined from five mice at the end. (C) In vivo efficacy in a murine BALB/c model of chronic TB
infection. Compounds were dosed orally 5 days a week for 4 weeks after infection withM. tuberculosis Erdman with a low-dose aerosol 21 days prior (start). Lung
and spleen CFU were determined from six mice at the end. **, P 0.01; *, P 0.001 (by pairwise multiple-comparison procedures [Tukey test] compared to
controls).
TABLE 5 Mitochondrial protein synthesis inhibitiona
Compound
Mean EC50 (M) SD
COX1 SDHA Cell viability
Compound 12 150 39.5  9.2 23.0  1.4
Compound 13 150 20.5  2.1 80.0  5.7
Compound 14 150 21.5  6.4 106  37.5
Linezolid 27.3  10.8 150 150
Chloramphenicol 31.4  23.2 150 110  14.1
Doxycycline 23.7  6.4 109  29 118  35.5
Erythromycin 150 150 150
a COX1 is cytochrome c oxidase, which is a mitochondrial protein that is synthesized by
mitochondrial ribosomes. SDHA is subunit A of the succinate dehydrogenase complex,
which is a mitochondrial protein that is synthesized by cytoplasmic ribosomes. Janus
green staining was used to determine cell viability after 7 days.
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In vitro and in vivo activities of compound 14. Since racemate
compound 11 had activity similar to that of isoniazid, which is an
in vitro bactericidal compound (32), in the GKO mouse model of
acute infection (Fig. 5B), we tested the pure enantiomer com-
pound 14 for in vitro bactericidal activity over 14 days at 20 times
its MIC (Fig. 6). The profile for compound 14 was very similar to
that of the bacteriostatic protein synthesis inhibitor linezolid,
which was different from that of moxifloxacin, a known bacteri-
cidal compound (33). Therefore, further tests of compound 14 in
a murine chronic TB infection model (Fig. 7) were performed in
parallel with the protein synthesis inhibitor linezolid. Compound
14 at 30 mg/kg QD showed good efficacy, resulting in a 2.4-log10
reduction in CFU, compared with a 2.6-log10 reduction in CFU
for 100 mg/kg of linezolid QD. In order to establish the optimal
dosing regimen for compound 14, we tested it in the murine
model of acute TB infection and compared efficacies using dosing
regimes of BID, QD, and every 48 h (q48h) (Fig. 8). Similar to
results with the chronic infection model, compound 14 was more
active at lower doses than linezolid, and q48h dosing was as effi-
cacious as QD or even BID dosing, which suggests that the pre-
liminary pharmacodynamic driver for efficacy was the AUC/MIC
ratio.
Resistance and LeuRS inhibitors. Emergence of resistance
during streptomycin monotherapy (34) and its noted reduction
by the addition of p-aminosalicylic acid (35, 36) lead to the para-
digm of combination TB drug therapy. The current core TB reg-
imen calls for a four-drug combination of isoniazid, rifampin,
ethambutol, and pyrazinamide. Although compound 14 has a
lower frequency of in vitro resistance than isoniazid (Table 6), the
emergence of resistance to epetraborole (GSK2251052/AN3365),
another 3-aminomethylbenzoxaborole LeuRS inhibitor, in a mi-
nority of patients in a complicated urinary tract infection trial
might suggest some caution (27). However, the addition of trim-
ethoprim to rifampin, which has a similar resistance problem, in a
urinary tract infection trial demonstrated the benefit of combina-
tion therapy in overcoming the emergence of rifampin-resistant
strains (37). This suggests that the risk from the emergence of
resistance to OBORT LeuRS inhibitors will likely be mitigated
when used in combination therapy.
Beneficial properties. Since combination therapy necessitates
a larger armamentarium than regular monotherapy, the demon-
stration for the first time that an oral AARS inhibitor can be a
potent antitubercular agent adds a potential new tool to fight TB,
which is timely noting the recent onset of totally drug-resistant
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FIG 6 M. tuberculosis H37Rv in vitro kill kinetics. Cells were incubated with
compounds at 20 times their MIC values for different times over 14 days in 10
ml of Middlebrook 7H9 medium containing 10% (vol/vol) ADC and 0.05%
(vol/vol) Tween 80. The MIC values used in this experiment were 0.013g/ml,
0.6 g/ml, and 0.06 g/ml for compound 14, linezolid, and moxifloxacin,
respectively. The means and the standard deviations of data from triplicate
cultures at each point are shown.
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FIG 7 Efficacy of compound 14 in a mouse model of chronic TB infection.
C57BL/6J mice were infected with M. tuberculosis H37Rv intratracheally
(102 CFU) and were dosed once daily for 8 weeks starting 6 weeks after
infection. Mice were sacrificed 24 h after the last drug administration. Every
column represents the mean values standard deviations of data from 7 mice
per group for untreated and linezolid-treated groups and from 3 mice for
compound 14-treated mice. *, P  0.001 by pairwise multiple-comparison
procedures (Tukey test) compared to controls.
FIG 8 Efficacy of compound 14 in a mouse model of acute TB infection under
different dosing regimes of once a day (QD), twice a day (BID), or every other
day (q48h). C57BL/6J mice were infected with M. tuberculosis H37Rv intratra-
cheally (105 CFU) and were dosed starting on the following day after infec-
tion for 8 days. Only one dose was administered on day 8 under the BID
schedule. Mice were sacrificed at least 24 h after the last drug administration.
Every dot represents one mouse data point except for linezolid (mean of data
for 5 mice standard deviation).
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(TDR) TB. In addition, the combination of low plasma protein
binding, molecular weight (207 to 285), and logD7.4 (
0.04 to
0.76) values, like the frontline TB drugs isoniazid, pyrazin-
amide, and ethambutol, suggests that this novel chemical class
deserves further optimization and, hopefully, progression into
clinical trials.
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